SIME Dx company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

simedx.com

Founded Year

2014

Stage

Unattributed - II | Alive

Total Raised

$830K

Last Raised

$630K | 2 yrs ago

About SIME Dx

SIME Dx is a platform company that specializes in personalized, data-driven preventative medicine.

SIME Dx Headquarter Location

80 Wood Lane

London, England, W12 0BZ,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SIME Dx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SIME Dx is included in 1 Expert Collection, including Digital Health.

D

Digital Health

12,812 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Latest SIME Dx News

SIME Dx announces new design for lung maturity diagnostic device

Aug 16, 2018

SIME Dx announces new design for lung maturity diagnostic device X SIME Dx, a digital molecular medicine company focused on the development and commercialisation of point-of-care (POC) diagnostics, has announced a new device design that fully automates the company's novel neonatal Lung Maturity Test (LMT). Image: SIME Dx has announced a new device design for lung maturity diagnostic device. Photo: courtesy of dream designs / FreeDigitalPhotos.net. Subscribe to our email newsletter LMT, the first application on the patented Digital Molecular Diagnostics (DMDx) platform, has been clinically proven to predict Respiratory Distress Syndrome (RDS) with high accuracy. RDS is the leading cause of morbidity and mortality in premature babies, and can only be prevented with early diagnosis and targeted treatment. LMT addresses this urgent unmet clinical need in the Neonatal Intensive Care Unit (NICU), where speed is critical and rapid screening has the potential to change the standard of care. To achieve real-time, lab-quality diagnostic results within minutes, SIME Dx developed an automated digital platform – DMDx. Powered by photonics and machine learning, DMDx measures multiple biomarkers simultaneously, in real-time, without the use of reagents or laboratory expertise. This transformative approach to diagnostics is ideal for POC and offers considerable advantages over central laboratory testing, such as fast and simple sample handling, early diagnosis and preventative care. To develop the LMT device, SIME Dx partnered with Integrated Technologies Limited (ITL), an award winning and innovative medical device design house and manufacturing group based in England, the United States and China. SIME Dx CEO Povl Verder said: “Completion of the LMT device design is a major milestone for SIME Dx. For the first time we are able to demonstrate exactly how our technology translates into a viable point-of-care product. “The focus is now on performance testing the device in a programme of clinical work in NICUs across Europe and China, as the company prepares for regulatory approval and early commercialisation.” This project was part funded by the EU Horizon2020 Phase II SME instrument, project number 666668. SIME Dx is a digital molecular medicine company developing novel point-of-care diagnostics. Our reagent-free platform, DMDx, analyses a single fluid sample for multiple biomarkers in real-time. Delivering precise diagnostic results to clinicians in critical moments. Our technology converges photonics, machine learning and medical science to enable preventative medicine. Source: Company Press Release

SIME Dx Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SIME Dx Rank

  • When was SIME Dx founded?

    SIME Dx was founded in 2014.

  • Where is SIME Dx's headquarters?

    SIME Dx's headquarters is located at 80 Wood Lane, London.

  • What is SIME Dx's latest funding round?

    SIME Dx's latest funding round is Unattributed - II.

  • How much did SIME Dx raise?

    SIME Dx raised a total of $830K.

  • Who are the investors of SIME Dx?

    Investors of SIME Dx include Microsoft ScaleUp and Oxford Technology Management.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.